Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Aura Minerals Q3 2025 Earnings Call - Record Production and EBITDA Fueled by Borborema Ramp-Up and High Gold Prices
Aura Minerals delivered a robust third quarter driven by ramping up Borborema to near full production and stable outputs from existing mines, culminating in 74,000 ounces produced and record EBITDA of...
- Aura Minerals produced a record 74,000 ounces in Q3 2025, up from 60,000 and 64,000 ounces in prior quarters, driven principally by Borborema ramping up near full production.
- Adjusted EBITDA reached a record $152 million in Q3, increasing 45% from the previous quarter and nearly doubling year-over-year, supported by higher gold prices and controlled costs.
- Gold prices averaged $3,473 in Q3, rising to around $4,000 per ounce recently, boosting future EBITDA but causing a $75 million non-cash mark-to-market loss on outstanding gold hedges.
- +7 more takeaways
Golar LNG Limited Q3 2025 Earnings Call - Firm $17 Billion EBITDA Backlog and Imminent Order of Fourth FLNG Unit
Golar LNG Limited reported a landmark third quarter in 2025, cementing its position as the sole proven provider of FLNG as a service. With a fully contracted fleet of three FLNGs under 20-year charter...
- Golar LNG’s existing fleet of three FLNG units is fully contracted on 20-year charters, generating a $17 billion EBITDA backlog pre-commodity and inflation adjustments.
- The company is advancing decisively on its fourth FLNG unit with three design options (Mark I, II, III) and plans to order long lead items imminently to lock delivery timelines amid supply pressures.
- Significant supply chain challenges exist, notably in gas turbines and cold boxes, driven by competition from AI data centers and LNG shipping sectors, causing cost inflation and longer lead times.
- +12 more takeaways
Ocugen Q3 2025 Earnings Call - Accelerating Gene Therapy Trials and Imminent BLA Submissions
Ocugen reported robust third quarter progress across its gene therapy portfolio targeting vision loss diseases. The company is advancing its lead candidate OCU400 swiftly toward a planned rolling BLA ...
- OCU400 gene therapy for Retinitis Pigmentosa is nearing completion of Phase 3 enrollment, with rolling BLA submission targeted in the first half of 2026 and commercial launch planned for 2027.
- OCU400 uses a gene-agnostic approach, potentially treating 98-99% of RP patients, vastly expanding beyond the current FDA-approved therapy targeting only 1-2%.
- OCU14ST for Stargardt disease enrollment is ahead of schedule in the pivotal Phase 2/3 GUARDIAN 3 clinical trial, with positive 12-month Phase 1 data showing significant lesion growth reduction and improved visual acuity.
- +7 more takeaways
Parsons Corporation Q3 2025 Earnings Call - Strong Organic Growth and Margin Expansion Despite Federal Contract Delays
Parsons Corporation delivered solid third quarter 2025 results, showcasing 14% total revenue growth excluding a winding-down confidential contract and a 60 basis point expansion in adjusted EBITDA mar...
- Parsons achieved 14% total revenue growth excluding the confidential contract, with 9% organic growth in Q3 2025.
- Adjusted EBITDA margin expanded 60 basis points to 9.8%, driven by improved program performance and accretive acquisitions.
- Critical Infrastructure segment posted 18% revenue growth and has maintained above 10% EBITDA margins for three consecutive quarters.
- +7 more takeaways
Humana Q3 2025 Earnings Call - Confident Growth Amid Operational Discipline and STARS Recovery
Humana delivered a solid Q3 in line with expectations, maintaining its 2025 EPS outlook of approximately $17 despite a challenging external environment. The company emphasized its focus on maximizing ...
- Humana reported Q3 2025 results in line with expectations, reaffirming full year EPS guidance of approximately $17.
- The company is focusing on maximizing customer lifetime value (LTV) by prioritizing member retention and delivering stable plan benefits to enhance retention and long-term profitability.
- Early data from the Annual Election Period (AEP) shows new sales tracking at the high end of expectations with an improved channel mix featuring direct and digital distribution targeting higher-value, engaged customers.
- +12 more takeaways
Avient Corporation Q3 2025 Earnings Call - Navigating Tough Markets with Productivity and Innovation-Driven Earnings Growth
Avient Corporation reported Q3 2025 adjusted EPS of $0.70, matching guidance despite softer-than-expected sales amid subdued global demand and uncertain macroeconomic conditions. The company’s operati...
- Q3 adjusted EPS $0.70 met guidance despite weaker sales versus strong Q3 2024 comps.
- Adjusted EBITDA margin expanded 60 basis points to 16.5%, driven by productivity and cost discipline.
- $40 million productivity benefits expected in 2025 from sourcing, Lean operations, and cost control.
- +17 more takeaways
Inogen Q3 2025 Earnings Call - Sustained Revenue Growth and Path to Profitability Amid Product Expansion
Inogen reported a solid Q3 2025 with over $92 million in revenue, marking its seventh consecutive quarter of mid-single-digit growth. Performance was fueled by strong adoption of portable oxygen conce...
- Inogen achieved over $92 million revenue in Q3 2025 representing seven consecutive quarters of mid-single-digit growth.
- International B2B revenues surged 19% year-over-year driven by expanding market share primarily in Europe and entering new markets.
- Domestic B2B channel delivered 7% growth, reflecting disciplined commercial execution and market-leading product portfolio strength.
- +12 more takeaways
Great Elm Capital Corp 3Q 2025 Earnings Call - Navigating NAV Hit from First Brands Bankruptcy Amid Strong Liquidity
Great Elm Capital Corp (GECC) reported a challenging third quarter in 2025, primarily due to a significant NAV impairment of approximately $16.5 million related to its over 5% exposure to First Brands...
- GECC faced a substantial NAV drop to $10.01 from $12.10 primarily due to First Brands bankruptcy affecting over 5% of portfolio allocation.
- First Brands loan went on non-accrual in Q3, halting interest income and causing a $16.5 million adverse NAV impact.
- Despite challenges, GECC raised equity at NAV, doubled revolver capacity to $50 million, and refinanced high-cost debt lowering interest by 100 basis points.
- +12 more takeaways
Trimble Q3 2025 Earnings Call - Strong Organic Growth, AI Integration, and Strategic Momentum Drive Raised Guidance
Trimble posted a robust third quarter with 11% organic revenue growth and 15% ARR growth, beating both top and bottom line expectations. The company reinforces its Connect and Scale strategy as the ba...
- Trimble’s Q3 2025 revenue rose 11% organically to $901 million, accompanied by a 15% ARR increase to $2.31 billion, with notable 17% growth in the AECO segment.
- Non-GAAP EPS was $0.81, up 16% year-over-year, reflecting operating leverage and model quality improvements, with gross margins expanding 90 basis points to 71.2%.
- Recurring revenue constituted 63% of Q3 revenue; software and services made up 78%, underscoring Trimble’s subscription-driven business model strength.
- +13 more takeaways
Lineage Logistics Q3 2025 Earnings Call - Navigating Excess Capacity and Tariff Headwinds with Stable Pricing and Operational Focus
Lineage Logistics reported a slightly better than expected Q3 2025 with revenue up 3% and adjusted EBITDA increasing 2% to a record $341 million. Despite a 3.6% year-over-year decline in same-store ne...
- Q3 2025 revenue grew 3%, with adjusted EBITDA up 2% to a record $341 million, but same-store NOI declined 3.6% year-over-year.
- Physical occupancy improved sequentially by 50 basis points to 75%, with expected further gains in Q4 despite a muted seasonal pattern.
- Pricing remains stable, with a 1-2% net increase in revenue per occupied pallet; no change to pricing strategy in Q3.
- +12 more takeaways